|
|
Board of Directors
Mr. Reinhard was a co-founder of Cardium Therapeutics, Inc., a publicly-traded medical technology company, which acquired InnerCool Therapies in March 2006. Mr. Reinhard has served as Chairman, Chief Executive Officer, President and Treasurer of Cardium since its formation in December 2003, and as Chairman and Chief Executive Officer of InnerCool Therapies since it was acquired by Cardium. For the past nine years, Mr. Reinhard has been focused on the commercial development of cardiovascular therapies. Before founding Cardium, he was a co-founder of Collateral Therapeutics, Inc., a former Nasdaq listed public company, and served as a director (from 1995) and President (from 1999) of Collateral Therapeutics until the completion of its acquisition by the Schering AG Group in 2002. He continued as Chief Executive of Collateral Therapeutics through December 2004. Mr. Reinhard played a major role in effecting Collateral Therapeutics’ initial public offering led by Bear Stearns & Co. in 1998, and the sale of Collateral Therapeutics to Schering AG. Mr. Reinhard has also been Executive Chairman (since 2004) of Artes Medical, Inc., a privately-held specialty pharmaceutical and medical device company. Previously, Mr. Reinhard was Vice President and Managing Director of the Henley Group, a publicly-traded diversified industrial and manufacturing group, and Vice President of various public and private companies created by the Henley Group through spin-out transactions, including Fisher Scientific Group, a leading international distributor of laboratory equipment and test apparatus for the scientific community, Instrumentation Laboratory and IMED Corporation, a medical device company. Mr. Reinhard received a B.S. in Finance and an M.B.A. from Babson College.
Dr. Dylan was a co-founder of Cardium Therapeutics, Inc., a publicly-traded medical technology company, which acquired InnerCool Therapies in March 2006. Dr. Dylan has served as a Director, General Counsel, Executive Vice President and Secretary of Cardium since its formation in December 2003, and as Chief Business Officer since May 2005. He has served as Executive Vice President, Chief Business Officer, General Counsel and Corporate Secretary of InnerCool Therapies since it was acquired by Cardium. Dr. Dylan has focused on the development of cardiovascular therapies for the last eight years. He served as General Counsel (from 1998) and Vice President (from 1999) of Collateral Therapeutics until the completion of its acquisition by the Schering AG Group in 2002. He continued as an executive officer of Collateral Therapeutics until October 2003. Dr. Dylan played a major role in developing Collateral Therapeutics’ intellectual property portfolio, in furthering its business development efforts and in advancing the company toward and through its acquisition by Schering AG. In addition to his work with Collateral Therapeutics, Dr. Dylan has advised both privately-held and publicly-traded companies that are developing, partnering or commercializing technology-based products. Before joining Collateral Therapeutics, Dr. Dylan was a partner with the law firm of Morrison & Foerster LLP. In his law firm practice, Dr. Dylan focused on the development, acquisition and enforcement of intellectual property rights, as well as related business and transactional issues. He also has worked with both researchers and business management in the biotech and pharmaceutical industries. Dr. Dylan received a B.Sc. in Molecular Biology from McGill University, Montreal, Canada; a Ph.D. in Biology from the University of California, San Diego, where he performed research at the Center for Molecular Genetics, and a J.D. from the University of California, Berkeley.
Mr. Mulroy has served as Chief Financial Officer of Cardium Therapeutics, Inc., a publicly-traded medical technology company, since November 2005 and as a director and Chief Financial Officer of InnerCool Therapies since it was acquired by Cardium in March 2006. Mr. Mulroy has over 20 years of corporate financial experience spanning several industries, having served most recently as Chief Financial Officer at Molecular Imaging Corporation, a publicly-traded diagnostic services company. Previously he held senior financial positions at public and privately-held companies, including SeraCare Life Sciences, Bioceutix Inc., Bidland Systems, First World Communications, River Medical Inc., IVAC Corp., Spectragrahics Corp. and IMED Corp. He is a Certified Public Accountant in the State Of California and began his career with Ernst & Young. Mr. Mulroy earned his degree in business administration from the University of San Diego.
|
